{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recombinant&page=17",
    "query": {
      "condition": "Recombinant",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 1029,
    "total_pages": 103,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recombinant&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recombinant&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T17:12:46.633Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01352793",
      "title": "A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningitis, Meningococcal"
      ],
      "interventions": [
        {
          "name": "rLP2086 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "control",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "10 Years to 25 Years"
      },
      "enrollment_count": 5715,
      "start_date": "2012-11",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-03-11",
      "last_synced_at": "2026-10-25T17:12:46.633Z",
      "location_count": 39,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01352793"
    },
    {
      "nct_id": "NCT00000721",
      "title": "An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CD4 Antigens",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 85,
      "start_date": null,
      "completion_date": "1991-03",
      "has_results": false,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-10-25T17:12:46.633Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000721"
    },
    {
      "nct_id": "NCT02563548",
      "title": "A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NSCLC",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "PEGPH20",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2015-10-22",
      "completion_date": "2019-03-26",
      "has_results": true,
      "last_update_posted_date": "2020-02-07",
      "last_synced_at": "2026-10-25T17:12:46.633Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02563548"
    },
    {
      "nct_id": "NCT05397119",
      "title": "A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza, Pandemic"
      ],
      "interventions": [
        {
          "name": "BW-1014: 25 µg rH5 in 20% NE - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BW-1014: 50 µg rH5 in 20% NE - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BW-1014: 100 µg rH5 in 20% NE - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rH5 (100 µg) control - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline (Placebo) - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H5N1 IIV - IM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BlueWillow Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-07-07",
      "completion_date": "2023-10-12",
      "has_results": true,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-25T17:12:46.633Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05397119"
    },
    {
      "nct_id": "NCT00456053",
      "title": "A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Anemia"
      ],
      "interventions": [
        {
          "name": "FG2216",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyntra Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2005-12",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2007-11-06",
      "last_synced_at": "2026-10-25T17:12:46.633Z",
      "location_count": 27,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00456053"
    },
    {
      "nct_id": "NCT00000681",
      "title": "A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma, Kaposi",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Bleomycin sulfate",
          "type": "DRUG"
        },
        {
          "name": "Vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Sargramostim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 24,
      "start_date": null,
      "completion_date": "1993-10",
      "has_results": false,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-10-25T17:12:46.633Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Buffalo, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000681"
    },
    {
      "nct_id": "NCT02895945",
      "title": "BAX 802 in CHA With Inhibitors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "12 Years to 75 Years · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2016-12-22",
      "completion_date": "2021-01-22",
      "has_results": true,
      "last_update_posted_date": "2021-10-20",
      "last_synced_at": "2026-10-25T17:12:46.633Z",
      "location_count": 3,
      "location_summary": "Peoria, Illinois • Winston-Salem, North Carolina • Cleveland, Ohio",
      "locations": [
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02895945"
    },
    {
      "nct_id": "NCT01572012",
      "title": "Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron + Hylenex",
          "type": "DRUG"
        },
        {
          "name": "Zofran ODT",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-02",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2014-01-24",
      "last_synced_at": "2026-10-25T17:12:46.633Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01572012"
    },
    {
      "nct_id": "NCT02163577",
      "title": "Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "X-linked Hypophosphatemia"
      ],
      "interventions": [
        {
          "name": "burosumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "5 Years to 12 Years"
      },
      "enrollment_count": 52,
      "start_date": "2014-07-02",
      "completion_date": "2018-10-30",
      "has_results": true,
      "last_update_posted_date": "2024-05-06",
      "last_synced_at": "2026-10-25T17:12:46.633Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02163577"
    },
    {
      "nct_id": "NCT05885412",
      "title": "A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)"
      ],
      "interventions": [
        {
          "name": "RP-A601",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Rocket Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2023-08-29",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-10-25T17:12:46.633Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Durham, North Carolina • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05885412"
    }
  ]
}